NLRP3 Inflammasome-Activated Microglia

Overview

NLRP3 Inflammasome-Activated Microglia
Cell Type	Activated microglia
Activation State	Pro-inflammatory (M1-like)
Key Feature	NLRP3 inflammasome assembly
Primary Output	IL-1β, IL-18 secretion
Brain Region	Throughout CNS
Associated Diseases	AD, PD, MS, stroke, TBI
KG Connections	View in Atlas

NLRP3 inflammasome-activated microglia are microglia that have undergone activation of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome complex, a multi-protein signaling platform that drives potent inflammatory responses. When activated, these microglia produce and secrete mature forms of the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18, which amplify neuroinflammation and can contribute to neuronal damage. NLRP3 inflammasome activation in microglia is implicated in virtually all major neurodegenerative and neuroinflammatory diseases, making it a central therapeutic target for neuroprotection.

The NLRP3 Inflammasome Complex

Structure and Components

The NLRP3 inflammasome is a cytosolic multi-protein complex consisting of:

1. NLRP3 (sensor protein): Contains leucine-rich repeats (LRR) for ligand sensing, a central NACHT domain for oligomerization, and a pyrin domain (PYD) for protein-protein interactions

2. ASC (apoptosis-associated speck-like protein containing a CARD): Adaptor protein linking NLRP3 to caspase-1 via its PYD and CARD domains

3. Pro-caspase-1: Inactive zymogen that becomes activated upon recruitment to the complex

4. Optional components: NEK7 (NIMA-related kinase 7), which facilitates NLRP3 oligomerization

Activation Mechanism (Two-Signal Model)

NLRP3 inflammasome activation requires two distinct signals:

Signal 1 (Priming): NF-κB-mediated transcriptional upregulation

• Triggered by: TLR ligands (LPS), TNF-α, IL-1β

• Upregulates: NLRP3, pro-IL-1β, pro-IL-18 gene expression

• Primes: Post-translational modifications of NLRP3 (deubiquitination, phosphorylation)

Signal 2 (Activation): Assembly and caspase-1 activation

• Triggered by diverse stimuli (see below)

• Results in: NLRP3 oligomerization → ASC speck formation → caspase-1 activation

• Outcomes: Pro-IL-1β/pro-IL-18 cleavage to mature cytokines; gasdermin D cleavage leading to pyroptotic cell death

Activating Stimuli in Microglia

Multiple damage-associated molecular patterns (DAMPs) and pathological signals activate microglial NLRP3:

• ATP: Extracellular ATP via P2X7 receptors → K⁺ efflux

• Protein aggregates: Amyloid-β, α-synuclein, tau oligomers → phagocytosis and lysosomal damage

• Crystals: Cholesterol crystals, uric acid → lysosomal disruption

• Mitochondrial dysfunction: mtDNA, ROS release

• Potassium efflux: Various mechanisms leading to low intracellular K⁺

• Calcium influx: Excessive Ca²⁺ entry

• Metabolic stress: Glucose deprivation, hypoxia

Functional Consequences

Cytokine Production

Activated caspase-1 cleaves:

• Pro-IL-1β → mature IL-1β: Potent pro-inflammatory cytokine that promotes neuroinflammation, induces COX-2, and enhances BBB permeability

• Pro-IL-18 → mature IL-18: Promotes IFN-γ production and Th1 responses

These cytokines amplify the inflammatory cascade by:

• Activating neighboring microglia and astrocytes

• Recruiting peripheral immune cells

• Inducing chemokine and adhesion molecule expression

• Impairing neuronal function and survival

Pyroptosis

Caspase-1 cleaves gasdermin D, forming pores in the plasma membrane that:

• Release IL-1β and IL-18 (lacking secretory signals)

• Cause lytic cell death (pyroptosis)

• Release DAMPs (ATP, HMGB1) that further activate neighboring cells

Pyroptotic microglial death perpetuates neuroinflammation through release of intracellular contents.

Altered Microglial Function

NLRP3-activated microglia exhibit:

• Enhanced phagocytosis (initially)

• Impaired debris clearance (chronically)

• Reduced neuroprotective functions

• Loss of homeostatic surveillance

• Secretion of neurotoxic factors (ROS, nitric oxide, glutamate)

Role in Neurological Disease

Alzheimer’s Disease

In Alzheimer’s disease:

• Amyloid-β oligomers and fibrils activate microglial NLRP3

• IL-1β promotes tau hyperphosphorylation and cognitive decline

• Chronic activation impairs Aβ clearance, creating a vicious cycle

• ASC specks released from pyroptotic microglia seed amyloid pathology

• NLRP3 knockout reduces pathology in AD mouse models

NLRP3 inhibition is a leading therapeutic strategy for AD.

Parkinson’s Disease

In Parkinson’s disease:

• α-synuclein aggregates potently activate NLRP3

• Dopaminergic neuron loss accelerated by IL-1β toxicity

• Neuroinflammation in substantia nigra driven by microglial NLRP3

• Genetic variants in NLRP3 associated with PD risk

• NLRP3 inhibition protects dopaminergic neurons in PD models

Multiple Sclerosis

In multiple sclerosis:

• NLRP3 activation contributes to demyelination

• IL-1β and IL-18 promote Th17 differentiation (pathogenic T cells)

• CNS inflammation perpetuated by microglial NLRP3

• EAE models show reduced severity with NLRP3 inhibition

Stroke and Traumatic Brain Injury

Following acute CNS injury:

• Massive ATP release and K⁺ fluctuations activate NLRP3

• Acute inflammation expands lesion size

• Chronic activation impairs functional recovery

• Therapeutic window: NLRP3 inhibition most effective if administered early

Aging

In normal aging:

• Chronic low-level NLRP3 activation contributes to “inflammaging”

• Accumulation of damage signals (oxidized lipids, dysfunctional mitochondria)

• Cognitive decline associated with elevated microglial IL-1β

• Senescent cells activate NLRP3 in surrounding microglia

Therapeutic Targeting

Small Molecule NLRP3 Inhibitors

Several selective inhibitors are in development:

• MCC950 (CP-456,773): First-generation specific NLRP3 inhibitor; highly effective in preclinical models but development halted due to hepatotoxicity

• OLT1177 (Dapansutrile): Oral NLRP3 inhibitor; clinical trials for heart disease and gout; potential CNS applications

• CY-09: Directly binds NLRP3 ATPase domain

• Tranilast: Repurposed anti-allergic drug; NLRP3 inhibitor with good safety profile

• Oridonin: Natural compound; covalently modifies NLRP3 cysteine residues

IL-1β Blocking Therapies

Targeting downstream products:

• Anakinra: IL-1 receptor antagonist (approved drug; poor BBB penetration)

• Canakinumab: Anti-IL-1β monoclonal antibody

• Both show efficacy in systemic inflammatory diseases; CNS applications limited by poor brain penetration

Caspase-1 Inhibitors

• VX-765 (Belnacasan): Prodrug inhibitor; CNS-penetrant; tested in epilepsy trials

• Broad effects beyond NLRP3 (inhibits all inflammasome-dependent caspase-1 activation)

Upstream Modulators

Targeting activation signals:

• P2X7 receptor antagonists: Block ATP-induced activation

• ROS scavengers: Reduce oxidative stress triggering

• Mitochondrial stabilizers: Prevent mtDNA/ROS release

• Lysosomal stabilizers: Reduce cathepsin B release

Cellular Therapies

• Microglial replacement: Transplanting non-activated microglia

• Engineered microglia: CRISPR-modified to lack NLRP3

• Exosome therapies: Delivering anti-inflammatory signals

Biomarkers and Detection

Identifying NLRP3-activated microglia:

• CSF IL-1β/IL-18 levels: Elevated in neuroinflammatory conditions

• PET imaging: TSPO ligands (general microglial activation); NLRP3-specific tracers in development

• Blood biomarkers: Circulating IL-1β, ASC specks

• Immunohistochemistry: ASC speck formation in tissue (post-mortem or biopsy)

Research Tools

Techniques for studying NLRP3-activated microglia:

• NLRP3-deficient mice: Genetic models revealing NLRP3 contributions

• ASC-Citrine mice: Visualize ASC speck formation in real-time

• Pharmacological inhibitors: Acute manipulations in vitro and in vivo

• Primary microglial cultures: Mechanistic studies with defined stimuli

• BV2/N9 cell lines: High-throughput screening platforms

Related Entities

• Microglia - Parent cell type

• Neuroinflammation - Process driven by NLRP3 activation

• IL-1β - Major cytokine product

• Alzheimer’s Disease - Disease with prominent NLRP3 activation

• Parkinson’s Disease - PD pathology involving NLRP3

• Pyroptosis - Cell death mechanism triggered by inflammasomes

• Astrocytes - Respond to microglial IL-1β